Summary of Treace Medical Concepts (TMCI) 2025 Investor Day Company Overview - Treace Medical Concepts was founded in 2014 with a mission to improve outcomes for bunion patients, achieving over $200 million in revenue primarily through a patented bunion procedure [2][3] - The company is entering a new growth phase with a comprehensive bunion solutions portfolio, aiming to address the significant problem of bunions, which can lead to painful and lifestyle-limiting deformities [3][4] Market Opportunity - Currently, Treace Medical has penetrated about 3% of the symptomatic surgical candidate base, with a goal to reach 7% to 8% to double the business in the coming years [3][4] - There are over 1 million symptomatic surgical candidates for bunion surgery, with high recurrence rates (60% to 70%) associated with traditional two-plane surgeries [4][5] - The company believes that its innovative Lapiplasty technology, which allows for comprehensive three-plane bunion correction, fills a significant gap in the market [4][5] Product Innovations - The Lapiplasty system has been adopted by nearly one-third of bunion surgeons by 2025, with ongoing iterations to improve reproducibility and minimize invasiveness [5][6] - New systems being launched include: - Nanoplasty and Percutoplasty 3D MIS osteotomy systems - SpeedMTP Rapid Compression Implant system - These innovations aim to address significant volume segments and expand access to the untapped 70% of surgeons' cases [6][8] Surgical Techniques and Philosophy - Treace Medical emphasizes a philosophy of teaching surgeons how to perform bunion surgeries effectively, which is seen as a key differentiator from competitors [34][35] - The company has developed a classification system for bunion treatment, recognizing four distinct categories of patients [11][12] - The focus is on achieving reproducible, consistent triplanar results with minimal incisions, reducing patient morbidity and improving recovery times [17][18] Competitive Landscape - Treace Medical's approach contrasts with competitors who may not provide adequate training or support for their surgical techniques [34][39] - The SpeedMTP system is highlighted as intuitive and easy to use, making it appealing to both surgeons and patients [40][41] Patient-Centric Approach - The company aims to change the perception of bunion surgery, traditionally viewed as painful and lengthy, by promoting minimally invasive techniques that offer faster recovery and less pain [50][60] - There is a growing demand for these techniques, particularly among patients who have previously avoided surgery due to fear of pain and recovery time [50][51] Conclusion - Treace Medical Concepts is positioned to lead the bunion surgery market with innovative technologies and a strong focus on surgeon education and patient outcomes, aiming to significantly increase market penetration and improve surgical results in the coming years [3][4][5]

Market Opportunity - The US bunion market represents a significant opportunity, with approximately 65 million Americans affected by bunions [9] - Of those affected, 44 million seek medical treatment annually [9] - The current US market for bunion surgical procedures is estimated at $23 billion, with a potential to exceed $5 billion [9] - Approximately 450,000 surgical procedures are performed annually, while an estimated 650,000 additional patients are in need of surgical treatment [9] Treace Medical Concepts' Position - Treace Medical Concepts, Inc is focused on improving outcomes for bunion patients, with a 5-year revenue CAGR of 40% [7] - The company's FY 2024 revenue reached $2094 million, representing a 12% increase, with a gross margin of 80% [7] - Approximately one-third of US foot surgeons are currently using Lapiplasty [7] Technology and Innovation - Treace is the pioneer and leader in 3D bunion surgery, protected by 117 US patents and pending patents [7] - Lapiplasty has demonstrated early weight bearing at an average of 77 days in a walking boot [19] - Lapiplasty has demonstrated 81% pain reduction with 89% improvement in MOxFQ walking/standing scores at 48 months [19] - Lapiplasty has demonstrated low recurrence rates of 08% (HVA >20°) & 84% (HVA >15°) at 48 months [19]